Abstracts tagged "pregnancy and treatment options"

Abstract Number: 2456 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Cecilia B. Chighizola², Teresa Del Ross³, Maria Gerosa⁴, Anna Kuzenko³, Maria Gabriella Raimondo⁴, Andrea Lojacono⁵, Sonia Zatti⁵, Francesca Ramazzotto⁵, Laura Trespidi⁶, Pier Luigi Meroni⁷, Vittorio Pengo³, Amelia Ruffatti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶L.Mangiagalli Obstetric Clinic, IRCSS Cà Granda, Ospedale Maggiore of Milano, Milano, Italy, ⁷Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milano, Italy
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results From a Multicenter Italian Cohort Over 20 Years Of Experience Background/Purpose: Antiphospholipid antibodies (aPL)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].